Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949600 | 0.81 | ACHE (0.33) | P2RX7ACHECYP3A4RAPGEF4HDAC1 | |
| SCHEMBL31713181 | 0.79 | TNF (0.38) | — | |
| SCHEMBL21598620 | 0.79 | TNF (0.38) | — | |
| SCHEMBL2578269 | 0.77 | ACHE (0.38) | P2RX7ACHECYP3A4RAPGEF4 | |
| SCHEMBL11261447 | 0.77 | ACHE (0.38) | ACHEHDAC1HDAC6 | |
| SCHEMBL4448667 | 0.75 | ALDH1A1 (0.36) | CYP3A4 | |
| SCHEMBL8249627 | 0.75 | ACHE (0.36) | P2RX7ACHECYP3A4RAPGEF4 | |
| SCHEMBL4623500 | 0.75 | ACHE (0.36) | ACHEPTGS2HDAC1HDAC6PTGS1 | |
| SCHEMBL31559780 | 0.75 | CYP3A4 (0.35) | CYP3A4 | |
| SCHEMBL29071566 | 0.75 | HTR2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032337-A1 | Process for producing substituted arylpyrazoles | LANTZSCH REINHARD (DE) | 2002-03-14 | — | — | US | claimed |
| CN-1220662-A | Process for preparing substituted arylpyrazoles | BAYER AG (DE) | 1999-06-23 | — | — | CN | claimed |
| EP-0904267-A1 | PROCESS FOR PRODUCING SUBSTITUTED ARYL PYRAZOLES | BAYER AG (DE) | 1999-03-31 | — | — | EP | claimed |
| WO-1997046534-A1 | PROCESS FOR PRODUCING SUBSTITUTED ARYL PYRAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-11 | — | — | WO | claimed |
| CN-101263131-B | Urea glucokinase activators | TRANSTECH PHARMA INC | 2013-04-24 | — | — | CN | disclosed |
| CN-102675221-A | Intermediate in method for preparing pyrimidinedione derivative | TAKEDA PHARMACEUTICAL | 2012-09-19 | — | — | CN | disclosed |
| CN-102140090-A | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL | 2011-08-03 | — | — | CN | disclosed |
| CN-102134230-A | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL | 2011-07-27 | — | — | CN | disclosed |
| CN-102134229-A | Dipeptidyl peptidase inhibitors | TAKAEDA CHEMICAL IND LTD | 2011-07-27 | — | — | CN | disclosed |
| CN-102134231-A | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL | 2011-07-27 | — | — | CN | disclosed |
| CN-102127053-A | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL | 2011-07-20 | — | — | CN | disclosed |
| CN-102127057-A | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL | 2011-07-20 | — | — | CN | disclosed |
| CN-1096449-C | Process for preparing substituted arylpyrazoles | BAYER AG (DE) | 2002-12-18 | — | — | CN | disclosed |
| US-6433210-B1 | HALOGENOARENE REACTED WITH A SUBSTITUTED ALKYNE, SUSBSTITUTED ARYLALKYNE FORMED IS REACTED WITH SODIUM HYDROXIDE AND THEN AN ACYLATING AGENT, AND THE ARYLALKINONE FORMED IS REACTED WITH HYDRAZINE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| US-20020032337-A1 | Process for producing substituted arylpyrazoles | LANTZSCH REINHARD (DE) | 2002-03-14 | — | — | US | disclosed |
| US-6118031-A | Process for producing substituted arylpyrazoles | BAYER AKTIENGESELLSCHAFT (DE) | 2000-09-12 | — | — | US | disclosed |
| US-6060605-A | Process for producing substituted arylpyrazoles | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-09 | — | — | US | disclosed |
| CN-1220662-A | Process for preparing substituted arylpyrazoles | BAYER AG (DE) | 1999-06-23 | — | — | CN | disclosed |
| EP-0904267-A1 | PROCESS FOR PRODUCING SUBSTITUTED ARYL PYRAZOLES | BAYER AG (DE) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997046534-A1 | PROCESS FOR PRODUCING SUBSTITUTED ARYL PYRAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032337-A1 | Process for producing substituted arylpyrazoles | CYP2F1, CYP1A1, CYP1B1 | P2RX7 2180/4885ACHE 4214/4885CYP3A4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.